Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
2.955
+0.255 (9.44%)
Aug 14, 2025, 12:04 PM - Market open
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
622.59M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SVRA News
- 1 day ago - Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update - Business Wire
- 26 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 2 months ago - Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation - Accesswire
- 2 months ago - Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday? - Benzinga
- 2 months ago - BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses - GlobeNewsWire
- 2 months ago - Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) - Business Wire
- 3 months ago - Savara Announces Participation in Jefferies Global Healthcare Conference - Business Wire
- 3 months ago - Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 - Business Wire